01—Abstract
Summary
Summary of the 10-K filed February 15, 2022. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. reported strong performance in its 2021 10-K filing, showcasing robust revenue growth driven by both its U.S. and International segments.
The company's diversified portfolio, with a significant contribution from companion animal products (60%a of revenue), highlights its resilience and market leadership in the animal health sector. Key growth drivers include increasing pet ownership, rising demand for quality animal protein, and the company's continuous innovation in medicines and vaccines. Zoetis's financial health appears solid, with significant cash reserves and manageable debt, supporting its ongoing investments in research and development and strategic acquisitions to further expand its offerings in diagnostics, precision animal health, and digital solutions.
Despite the positive financial outlook, investors should be aware of the competitive landscape and potential risks, including patent expirations for certain key products and the ongoing impact of global economic conditions and regulatory changes. The company's strategic focus on innovation, customer experience, digital leadership, and sustainability positions it well for future growth, making it an attractive prospect for long-term investors in the animal health industry.
02—Key points
Key Highlights
- Zoetis reported a 16% increase in total revenue to $7.78 billion in 2021, driven by strong performance in both the U.S. and International segments.
- Companion animal products represented 60% of total revenue, emphasizing the growing demand for pet healthcare, while livestock products accounted for 39%.
- The company's top two products, Apoquel and Simparica/Simparica Trio, each contributed approximately 10% of revenue, with the top five products contributing 33%.
- Research and Development (R&D) expenses increased by 10% to $508 million, reflecting continued investment in innovation and new product development.
- Zoetis maintained a strong liquidity position with $3.49 billion in cash and cash equivalents and robust operating cash flow.
- The company announced significant share repurchase programs, demonstrating a commitment to returning value to shareholders.
- Key product launches and expansions in diagnostics and precision animal health are strategically positioning Zoetis for continued growth in evolving market segments.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 15, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $7.78B$6.67B | +16.5% |
| Cost of Revenue | $2.30B$2.06B | +12.0% |
| Gross Profit | $5.47B$4.62B | +18.5% |
| SG&A Expenses | $2.00B$1.73B | +15.9% |
| Interest Expense | $224.00M$231.00M | −3.0% |
| Net Income | $2.03B$1.64B | +24.3% |
| EPS (Basic) | $4.29$3.44 | +24.7% |
| EPS (Diluted) | $4.27$3.42 | +24.9% |
| Shares Outstanding (Basic) | 474.35M475.50M | −0.2% |
| Shares Outstanding (Diluted) | 476.72M478.57M | −0.4% |
05—Questions
Frequently Asked Questions
What was Zoetis's overall financial performance in 2021?
Zoetis demonstrated strong financial performance in 2021, with total revenue increasing by 16% to $7.78 billion. Net income attributable to Zoetis also saw a significant increase of 24% to $2.04 billion. The company's financial health is further supported by substantial cash reserves and manageable debt levels.
How diversified is Zoetis's revenue stream?
Zoetis has a highly diversified revenue stream, with 60% of its revenue coming from companion animal products and 39% from livestock products. This diversification across species and product categories (medicines, vaccines, diagnostics) provides stability and resilience. The company also operates in both the U.S. (52% of revenue) and International (47% of revenue) markets.
What are the key growth drivers and strategic priorities for Zoetis?
Key growth drivers include increasing pet ownership and spending on pet care, growing global demand for animal protein, and advancements in veterinary medicine. Zoetis's strategic priorities are focused on driving innovative growth through R&D and acquisitions, enhancing customer experience, leading in digital and data analytics, cultivating a high-performing organization, and championing a healthier, more sustainable future.
What are the main risks and challenges Zoetis faces?
Zoetis faces risks including intense competition, potential safety or efficacy concerns with products, patent expirations on key products (leading to generic competition), changes in distribution channels (especially for companion animal products), and the impact of global economic conditions, regulatory changes, and potential animal disease outbreaks. The company also notes cybersecurity risks and the need to protect intellectual property.
06—Continue